Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $489,693.75 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 13,125 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $37.31, for a total value of $489,693.75. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The stock was sold at an average price of $38.02, for a total value of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07.

Harmony Biosciences Stock Up 0.4 %

Shares of HRMY stock traded up $0.17 on Tuesday, reaching $38.42. 519,661 shares of the company were exchanged, compared to its average volume of 579,787. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 18.21, a PEG ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a 50-day moving average of $34.86 and a 200-day moving average of $35.12. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter last year, the firm posted $0.63 EPS. Harmony Biosciences’s revenue was up 16.0% compared to the same quarter last year. Analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

HRMY has been the subject of a number of recent research reports. Oppenheimer restated an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Mizuho raised their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $55.00.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in HRMY. GAMMA Investing LLC boosted its stake in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC boosted its position in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after buying an additional 965 shares during the last quarter. CWM LLC grew its holdings in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares in the last quarter. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Harmony Biosciences during the 3rd quarter valued at $74,000. 86.23% of the stock is owned by institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.